Novartis Pharms Corp Drug Patent Portfolio
Novartis Pharms Corp owns 2 orange book drugs protected by 19 US patents Given below is the list of Novartis Pharms Corp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11058667 | Sacubitril-valsartan dosage regimen for treating heart failure | 09 May, 2036 | Active |
| US9283209 | Oral formulations of deferasirox | 21 Nov, 2034 | Active |
| US11135192 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling | 22 Aug, 2033 | Active |
| US9517226 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling | 22 Aug, 2033 | Active |
| US9937143 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling | 22 Aug, 2033 | Active |
| US8877938 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations | 27 Nov, 2027 | Active |
| US8877938 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations | 27 May, 2027 | Active |
| US9388134 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations | 08 May, 2027 | Active |
| US9388134 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations | 08 Nov, 2026 | Active |
| US8101659 | Methods of treatment and pharmaceutical composition | 15 Jul, 2025 | Active |
| US8101659 | Methods of treatment and pharmaceutical composition | 15 Jan, 2025 | Active |
| US7468390 | Methods of treatment and pharmaceutical composition | 27 May, 2024 | Expired |
| US7468390 | Methods of treatment and pharmaceutical composition | 27 Nov, 2023 | Expired |
| US8404744 | Methods of treatment and pharmaceutical composition | 14 Jul, 2023 | Expired |
| US8796331 | Methods of treatment and pharmaceutical composition | 14 Jul, 2023 | Expired |
| US8404744 | Methods of treatment and pharmaceutical composition | 14 Jan, 2023 | Expired |
| US8796331 | Methods of treatment and pharmaceutical composition | 14 Jan, 2023 | Expired |
| US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | 05 Apr, 2019 | Expired |
| US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | 24 Jun, 2017 | Expired |
Latest Legal Activities on Novartis Pharms Corp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Novartis Pharms Corp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 May, 2024 | US9517226 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Dec, 2023 | US9388134 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Aug, 2023 | US9283209 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jul, 2023 | US8101659 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2022 | US8877938 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jan, 2022 | US8796331 |
| Post Issue Communication - Certificate of Correction | 18 Jan, 2022 | US9937143 |
| Post Issue Communication - Certificate of Correction | 18 Jan, 2022 | US9517226 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Oct, 2021 | US11135192 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Oct, 2021 | US11135192 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Sep, 2021 | US9937143 |
|
Email Notification
Critical
| 16 Sep, 2021 | US11135192 |
|
Issue Notification Mailed
Critical
| 15 Sep, 2021 | US11135192 |
|
Issue Fee Payment Verified
Critical
| 02 Sep, 2021 | US11135192 |
| Dispatch to FDC | 02 Sep, 2021 | US11135192 |
Novartis Pharms Corp's Drug Patent Litigations
Novartis Pharms Corp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 07, 2020, against patent number US8101659. The petitioner Biocon Pharma Limited, challenged the validity of this patent, with Novartis Pharmaceuticals Corporation as the respondent. Click below to track the latest information on how companies are challenging Novartis Pharms Corp's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8101659 | August, 2020 |
Terminated-Denied
(16 Feb, 2021)
| Novartis Pharmaceuticals Corporation | Biocon Pharma Limited |
Novartis Pharms Corp Drug Patents' Oppositions Filed in EPO
Novartis Pharms Corp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 21, 2008, by Mundipharma Gmbh. This opposition was filed on patent number EP03704413A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP13750725A | Jan, 2022 | STADA Arzneimittel AG | Revoked |
| EP13750725A | Jan, 2022 | Generics [UK] Limited | Revoked |
| EP13750725A | Jan, 2022 | Algemeen Octrooi- en Merkenbureau B.V. | Revoked |
| EP13750725A | Jan, 2022 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP13750725A | Jan, 2022 | Wuesthoff & Wuesthoff Patentanwälte PartG mbB | Revoked |
| EP13750725A | Jan, 2022 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP10176094A | Apr, 2021 | Krka, d.d., Novo mesto | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | betapharm Arzneimittel GmbH | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | D Young & Co LLP | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Granted and Under Opposition |
| EP10176094A | Jan, 2021 | Generics [UK] Limited | Granted and Under Opposition |
| EP14710654A | Jul, 2019 | INVOKAT Intellectual Property Services | Patent maintained as amended |
| EP14710654A | Jul, 2019 | HGF Limited | Patent maintained as amended |
| EP14710654A | Jul, 2019 | Teva Pharmaceutical Industries Ltd | Patent maintained as amended |
| EP16188627A | Sep, 2018 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP16188627A | Sep, 2018 | HGF Limited | Granted and Under Opposition |
| EP06827689A | Oct, 2014 | Maiwald Patentanwalts GmbH | Revoked |
| EP03704413A | May, 2008 | Mundipharma GmbH | Opposition procedure closed |
Novartis Pharms Corp's Family Patents
Novartis Pharms Corp drugs have patent protection in a total of 53 countries. It's US patent count contributes only to 17.7% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Novartis Pharms Corp Drug List
Given below is the complete list of Novartis Pharms Corp's drugs and the patents protecting them.
1. Entresto
Entresto is protected by 16 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11058667 | Sacubitril-valsartan dosage regimen for treating heart failure |
09 May, 2036
(11 years from now)
| Active |
| US11135192 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
22 Aug, 2033
(8 years from now)
| Active |
| US9517226 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
22 Aug, 2033
(8 years from now)
| Active |
| US9937143 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
22 Aug, 2033
(8 years from now)
| Active |
| US8877938
(Pediatric)
| Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
27 Nov, 2027
(3 years from now)
| Active |
| US8877938 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
27 May, 2027
(2 years from now)
| Active |
| US9388134
(Pediatric)
| Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
08 May, 2027
(2 years from now)
| Active |
| US9388134 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
08 Nov, 2026
(1 year, 11 months from now)
| Active |
| US8101659
(Pediatric)
| Methods of treatment and pharmaceutical composition |
15 Jul, 2025
(7 months from now)
| Active |
| US8101659 | Methods of treatment and pharmaceutical composition |
15 Jan, 2025
(a month from now)
| Active |
| US7468390
(Pediatric)
| Methods of treatment and pharmaceutical composition |
27 May, 2024
(5 months ago)
| Expired |
| US7468390 | Methods of treatment and pharmaceutical composition |
27 Nov, 2023
(11 months ago)
| Expired |
| US8404744
(Pediatric)
| Methods of treatment and pharmaceutical composition |
14 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US8796331
(Pediatric)
| Methods of treatment and pharmaceutical composition |
14 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US8404744 | Methods of treatment and pharmaceutical composition |
14 Jan, 2023
(1 year, 10 months ago)
| Expired |
| US8796331 | Methods of treatment and pharmaceutical composition |
14 Jan, 2023
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entresto's drug page
2. Jadenu
Jadenu is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9283209 | Oral formulations of deferasirox |
21 Nov, 2034
(10 years from now)
| Active |
| US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
05 Apr, 2019
(5 years ago)
| Expired |
| US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
24 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jadenu's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List